Assessment of the effect of single dose dexamethasone on the hypothalamic-pituitary axis
Phase 4
Completed
- Conditions
- hypothalamic-pituitary axis suppressionpostoperative nausea and vomitingMetabolic and Endocrine - Normal metabolism and endocrine development and functionAnaesthesiology - Other anaesthesiology
- Registration Number
- ACTRN12611001067965
- Lead Sponsor
- Dr Marianne Elston
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
Healthy male volunteers
Exclusion Criteria
Glucocorticoid use within the past 6 months
Psychiatric illness
Uncontrolled hypertension
Diabetes mellitus
Shift workers
Unable to give informed consent
Medications likely to interfere with dexamethasone metabolism
Hypothalamic-pituitary target organ axis disease
Acute illness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percent cortisol suppression based on 0800hr plasma cortisol measurement pre- and 23-hours post-dexamethasone. Samples for cortisol obtained by blood collection.[23 hours post-dexamethasone administration]
- Secondary Outcome Measures
Name Time Method Percent reduction in Synacthen-stimulated plasma cortisol levels obtained by blood collection.<br>Synacthen testing will be performed pre-dexamethasone and at 24 hours post-dexamethasone administration[24 hours post-dexamethasone administration];Percent reduction in thyroid hormone levels. Thyroid hormone levels will be measured by blood analysis.[24 hours post-dexamethasone administration];Percent reduction in gonadal hormones. Gonadal hormones will be measured by blood analysis.[24 hours post-dexamethasone administration];Duration of cortisol suppression. Plasma cortisol will be measured by blood analysis.[24 hours, 48 hours, 72 hours, 96 hours post dexamethasone administration]